Companies / Janux Therapeutics, Inc.
Janux Therapeutics, Inc.
Nasdaq: JANXCIK 1817713SAN DIEGO, CA
Financials
Ownership
61.1M shares outstanding · as of Aug 4, 2026
Ownership
| Insiders | 0.63% | 383,190 |
| 10%+ / strategic | 12.05% | 7,366,335 |
| Institutions | 91.62% | 56,011,891 |
| Public float | 0.00% | 0 |
Reported holdings exceed shares outstanding — public float shown as 0; some positions may overlap or lag.
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 16
View all →| Insider | % of shares | Shares |
|---|---|---|
Campbell David AlanCEOFormerPresident and CEO · Director | 0.62% | 381,582 |
DiRaimondo ThomasChief Scientific Officer | 0.25% | 155,825 |
Winter Charles M.FormerChief Technical Officer | 0.17% | 106,321 |
Meyer Andrew HollmanFormerChief Business Officer | 0.14% | 83,095 |
Doyle Janeen NoelChief Corp. & Bus. Dev. Ofcr | 0.13% | 80,000 |
Capps Vickie LDirector | 0.13% | 79,598 |
McIver ZachariahChief Medical Officer | 0.09% | 52,286 |
Go WilliamFormerChief Medical Officer | 0.07% | 44,000 |
Dobek MariaFormerVice President, Accounting | 0.06% | 34,308 |
Dobmeier EricDirector | 0.03% | 15,481 |
Institutional holders 188
View all →| Holder | Value | % of shares |
|---|---|---|
| $155.54M | 18.30% | |
| $94.23M | 10.03% | |
| $58.28M | 6.86% | |
| $48.47M | 5.75% | |
| $46.16M | 4.92% | |
| $40.11M | 4.75% | |
| $33.02M | 3.91% | |
| $24.70M | 2.93% | |
| $22.22M | 2.63% | |
| $17.96M | 2.13% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | BlackRock, Inc. 13F manager | Add | — | $31.56M | +2.1M +50.35% | 6,134,667 10.03% of shares | medium |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | Trim | — | $-16.03M | -1.2M -21.57% | 4,196,409 6.86% of shares | medium |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Trim | — | $-13.49M | -971K -49.67% | 983,600 1.61% of shares | medium |
| Q2 2026 as of | State Street Corporation 13F manager | Trim | — | $-13.04M | -849K -22.03% | 3,004,899 4.92% of shares | medium |
| Q1 2026 as of | Tang Capital Management, LLC 13F manager | New | — | $6.95M | +500K | 500,000 0.82% of shares | medium |
| Q3 2024 as of | Barclays PLC 13F manager | Add | — | $6.58M | +145K +496.55% | 174,061 0.28% of shares | medium |
| Q1 2026 as of | Adage Capital Partners Gp, L.L.C. 13F manager | Exit | — | $-5.52M | -400K -100.00% | — | medium |
| Q1 2025 as of | Barclays PLC 13F manager | Trim | — | $-5.30M | -196K -74.33% | 67,766 0.11% of shares | medium |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Janus Henderson Group PLC | Passive13G/A | — |
| Prosight Management, LP | Passive13G | — |
| Fmr LLC | Passive13G/A | — |
| State Street Corporation | Passive13G | — |
| Janus Henderson Group PLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| JANX | — | 47103J105 |